Northwest Biotherapeutics (NWBO) Preferred Stock Liabilities (2010 - 2026)

Northwest Biotherapeutics' Preferred Stock Liabilities history runs 11 years deep, the most recent figure standing at $12.5 million for Q1 2026.

• In Q1 2026, Preferred Stock Liabilities fell 14.73% year-over-year to $12.5 million; the TTM figure through Mar 2026 stood at $12.5 million (down 14.73% YoY), while the FY2025 annual figure was $12.7 million, down 18.04% from the prior year.
• Preferred Stock Liabilities for Q1 2026 stood at $12.5 million, down from $12.7 million in the prior quarter.
• The five-year high for Preferred Stock Liabilities was $27.7 million in Q3 2023, with the low at $12.5 million in Q1 2026.
• The 5-year median for Preferred Stock Liabilities is $15.9 million (2024), against an average of $18.0 million.
• The sharpest annual moves came in 2023 and 2024: Preferred Stock Liabilities soared 101.27% in 2023, then plunged 42.61% in 2024.
• Northwest Biotherapeutics' Preferred Stock Liabilities stood at $23.1 million in 2022, then decreased by 18.83% to $18.7 million in 2023, then declined by 17.15% to $15.5 million in 2024, then declined by 18.04% to $12.7 million in 2025, then declined by 1.78% to $12.5 million in 2026.
• Business Quant data shows NWBO's Preferred Stock Liabilities at $12.5 million in Q1 2026, $12.7 million in Q4 2025, and $13.4 million in Q3 2025.